MicroRNA 1302-10 (MIR1302-10)

MicroRNA 1302-10 (MIR1302-10) is a member of the miR-1302 family, which consists of short (20-24 nucleotide) non-coding RNAs known as microRNAs (miRNAs). miRNAs function primarily at the post-transcriptional level, regulating gene expression by targeting messenger RNAs (mRNAs) for degradation or translational repression. The miR-1302 family is derived from MER53 DNA transposable elements and is specific to placental mammals. Like other family members, MIR1302-10 is predicted to be processed from a stem-loop precursor and incorporated into the RNA-induced silencing complex (RISC), which mediates its regulatory function. Currently, the specific biological roles, disease associations, and interacting drugs for MIR1302-10 have not been characterized in the literature[1][2][5]. MIR1302-10 is not considered a conventional therapeutic target (such as a receptor, enzyme, transporter, etc.), and there is no evidence for direct pharmacological targeting or drug interaction[1][5]. There is no information on its function as a biomarker, safety concerns, or clinical utility. The abbreviation and aliases are consistently reported as MIR1302-10 or hsa-mir-1302-10. No specific disease role, functional studies, or clinical relevance are established for this family member as of current knowledge[2][5]. miR-1302-10 is a predicted and not experimentally validated miRNA without established function. Many such miRNAs are annotated based on sequence but lack biological characterization, so listing it as a drug target or clinically actionable entity would be incorrect at this time[1][2][5].

Other names

hsa-mir-1302-10MIR1302-10